English
Français
Deutsch
Italiano
Português
Русский
Español
ไทย
Türkçe
简体中文
日本語
한국어
हिन्दी
Over the past 3 months, 33 analysts have published their opinion on Biogen (NASDAQ:BIIB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company’s business to predict how a stock will trade over the upcoming year.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 14 | 16 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 4 | 5 | 2 | 0 | 0 |
| 2M Ago | 6 | 6 | 1 | 0 | 0 |
| 3M Ago | 4 | 4 | 0 | 0 | 0 |
These 33 analysts have an average price target of $332.03 versus the current price of Biogen at $266.365, implying upside.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
